Aikido granted sublicense to technology for targeted psilocybin treatment of neuro-inflamed tissue in cancer patients

New york, april 7, 2021 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki) ("aikido" or the "company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (cns) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients.   the homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed cns tissue.
DOMH Ratings Summary
DOMH Quant Ranking